Rhumbline Advisers Kymera Therapeutics, Inc. Call Options Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KYMR
# of Institutions
166Shares Held
63.1MCall Options Held
22.6KPut Options Held
14.4K-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$319 Million0.02% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$299 Million2.38% of portfolio
-
Atlas Venture Life Science Advisors, LLC5.35MShares$267 Million21.28% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$257 Million4.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.82MShares$240 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.73B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...